(Q43696321)

25 November 2017

0 references

Fluconazole vs. amphotericin B for the management of candidaemia in adults: a meta-analysis (English)

1 reference

25 November 2017

1 reference

1 reference

1 reference

1 reference

Kontoyiannis DP

1

1 reference

25 November 2017

Bodey GP

series ordinal

2

1 reference

25 November 2017

Mantzoros CS

series ordinal

3

1 reference

25 November 2017

publication date

1 January 2001

1 reference

25 November 2017

1 reference

25 November 2017

volume

44

1 reference

25 November 2017

issue

5

1 reference

25 November 2017

page(s)

125-135

1 reference

International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1439-0507.2001.00649.X

21 January 2018

Azole Antifungal Agents

1 reference

https://api.crossref.org/works/10.1046%2FJ.1439-0507.2001.00649.X

Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1439-0507.2001.00649.X

Using systematic reviews in clinical education

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1439-0507.2001.00649.X

Quantitative synthesis in systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1439-0507.2001.00649.X

Formulating questions and locating primary studies for inclusion in systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1439-0507.2001.00649.X

Selecting and appraising studies for a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1439-0507.2001.00649.X

Integrating heterogeneous pieces of evidence in systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1439-0507.2001.00649.X

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1439-0507.2001.00649.X

APACHE II: a severity of disease classification system

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1439-0507.2001.00649.X

Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1439-0507.2001.00649.X

Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: a prospective randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1439-0507.2001.00649.X

Systemic amphotericin B versus fluconazole in the management of antibiotic resistant neutropenic fever — preliminary observations from a pilot, exploratory study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1439-0507.2001.00649.X

Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1439-0507.2001.00649.X

Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1439-0507.2001.00649.X

Comparative study of the efficacy of fluconazole versus amphotericin B/flucytosine in surgical patients with systemic mycoses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1439-0507.2001.00649.X

Evaluation of new antifungal drugs for the treatment of systemic fungal infections. Infectious Diseases Society of America and the Food and Drug Administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1439-0507.2001.00649.X

Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1439-0507.2001.00649.X

Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1439-0507.2001.00649.X

Problems and controversies in the management of hematogenous candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1439-0507.2001.00649.X

Candida sepsis in surgical patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1439-0507.2001.00649.X

A prospective study of the efficacy of fluconazole (UK-49,858) against deep-seated fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1439-0507.2001.00649.X

Secondary mycosis in surgery: treatment with fluconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1439-0507.2001.00649.X

Etiologic organisms as independent predictors of death and morbidity associated with bloodstream infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1439-0507.2001.00649.X

Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1439-0507.2001.00649.X

Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Te

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1439-0507.2001.00649.X

10.1046/J.1439-0507.2001.00649.X

21 January 2018

Identifiers

DOI

1 reference

25 November 2017

1 reference